GNE

Across TCGA pan-cancer cohorts, GNE Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GNE data layer compared with 22 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher GNE Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GNE expression acts as an unfavorable survival marker.

LUSC, PRAD, and BRCA are the cancer types where GNE Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	II,III,IV	0.135	0.663	.015	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BRCA	DFS	Median	III,IV	0.126	0.493	.027	4	view →
ACC	DFS	Median	All	0.140	0.666	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GNE–LUSC (DFS)

Open the LUSC breakdown →